Table 1.

Likelihood of clinical improvement (day 14) and survival (days 30 and 90) in both periods, stratified by CRP response* (up to day 13)

		Likelihood (P)
		Period 1, control patients	Period 2, patients on active treatment	Periods 1 and 2, all patients
Improvement at 14 days	ΔCRPno	0.24 (17/72)†	0.33 (7/21)	0.26 (24/93)
	ΔCRPyes	0.88 (7/8)	0.75 (49/65)	0.77 (56/73)
	All	0.30 (24/80)	0.65 (56/86)	0.48 (80/166)
Survival at 30 days	ΔCRPno	0.49 (35/72)	0.57 (12/21)	0.51 (47/93)
	ΔCRPyes	1.0 (8/8)	0.91 (59/65)	0.92 (67/73)
	All	0.54 (43/80)	0.83 (71/86)	0.69 (114/166)
Survival at 90 days	ΔCRPno	0.49 (35/72)	0.57 (12/21)	0.51 (47/93)
	ΔCRPyes	1.0 (8/8)	0.85 (55/65)	0.86 (63/73)
	All	0.54 (43/80)	0.78 (67/86)	0.66 (110/166)

Figures in brackets reflect the number of patients (n/N).

*The ΔCRP threshold for a ‘good CRP response’ was defined as 80% decrease from baseline based on receiver operator characteristic analysis.

†0 ≤ likelihood (P) ≤1.

CRP, C reactive protein.